Endometrial cancer is the fourth most common cancer in women, and its incidence is increasing. Early detection is fundamental to patients’ survival. Currently, no screening methods are available and diagnosis is a multistep process that includes minimally-invasive and invasive tests. This inaccurate diagnostic process is a burden on our healthcare system.

This funded project aims is to advance the development of a non-invasive, objective, and personalised diagnostic tool of endometrial cancer using cervical fluid protein biomarkers and clinical data. In this proposal, we will validate protein biomarkers in a retrospective clinical study coordinated by VHIR (Spain) and with the top-edge technology on targeted proteomics, led by the LIH partner (Luxembourg). Molecular markers will be combined with clinical data by the USC partner (Spain) and the most promising biomarkers will be transferred to an antibody technology by ICOSAGEN (Estonian SME partner) and SolarBiotec (Turkey SME partner). Throughout the project, the HU partner (Turkey) and VHIR will ensure the clinical validation of the developed non-invasive tool and the valorisation of the asset to meet the stakeholders’ requirements. The resulting tool is a change in the paradigm on how endometrial cancer patients are managed and will benefit patients, doctors and the health system.